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Abstract
Crohn disease (CD) with complications such as penetrating, stricturing, and perianal disease is called complicated CD. The aim of this
study is to test the efficiency with which the CD8+CD28+/CD8+CD28– cell balance can predict a subsequent active stage in patients
with newly diagnosed complicated CD.
Seventeen patients with complicated CD and 48 CD patients with no complications were enrolled. Blood CD8+ T cells were tested
from all of the 65 newly diagnosed CD patients upon enrollment. The potential risk factors were compared between the 2 groups. A
30-week follow-up was performed, and the efficiency of the CD8+ cell balance at predicting active CD was analyzed using receiver-
operating characteristic curves. The cumulative remission lasting rates (CRLRs) were analyzed using the Kaplan–Meier method.
Compared with the control CD group, patients with complicated CD were predominantly male and younger in age; they also had
lower body mass indices (BMIs), higher Crohn disease activity indices (CDAIs), higher immunosuppressant and steroid prescription
rates, and significantly higher surgical rates. The CD8+CD28+/CD8+CD28– balance was associated with BMI, CDAI, steroids, and
surgery. The CD8+CD28+/CD8+CD28– ratios were significantly lower at week 0 and on the 6th, 22nd, and 30th week during follow-
up with a shorter lasting time of remission for the complicated CD patients. The CD8+CD28+/CD8+CD28– ratio could accurately
predict the active stage for the patients with complicated CD, and the highest sensitivity (89.2%) and specificity (85.3%) were found
when the ratio was 1.03. Treatment with steroids and surgery, along with a significantly lower CD8+CD28+/CD8+CD28– ratio and
lower CRLRs, was closely related to a worse outcome for the patients with complicated CD.
Patients requiring steroids and surgery experience more severe disease activity and thus a disequilibrated immunological balance,
which could be the main reason for a decreased CD8+CD28+/CD8+CD28– ratio. This ratio can sensitively predict the active stage for
patients with complicated CD, and more care should be taken when this ratio is <1.03.
Abbreviations: BA = biological agent, CD = Crohn disease, CRLRs = cumulative remission lasting rates, IBD = inflammatory
bowel disease, LTR = lasting time of remission, ROC = receiver-operating characteristic, UC = ulcerative colitis.
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1. Introduction be 1.37 per 100,000 individuals in Asia and 3.44 per 100,000Significant changes have been witnessed in the geographical
distribution of inflammatory bowel disease (IBD); IBD has shifted
from the developed world, with a high incidence rate, to
traditionally low-incidence regions such as Asia, South America,
Southern and Eastern Europe.[1] The incidence rate is estimated toEditor: Bülent Kantarçeken.
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individuals in China, which has the highest IBD incidence in
Asia,[2] emphasizing the need for specific health care resources in
developing countries.
However, Crohn disease (CD) is more difficult to diagnose
than ulcerative colitis (UC) because of CD’s atypical and
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Dai et al. Medicine (2017) 96:26 Medicineapproximately 52% in Asia, are finally diagnosed upon the
appearance of parenteral complications, including penetrating,
stricturing, perianal disease, intraperitoneal abscess, or other
parenteral manifestations; these cases are classified as complicat-
ed CD.[2] Almost all gastroenterologists attempt to find
biomarkers or risk-prediction models to aid in early diagnosis
and prognosis prediction for CD. However, no validated,
inexpensive, or sensitive models for the prediction of risk are
available for complicated CD.[3] Increasing evidence shows that T
cells, including CD4+ and CD8+ T cells and especially regulatory
T cells (Tregs, mainly consisting of CD4+CD25+[4] and
CD8+CD28– T cells[5]), play a primary role in the immunologic
pathogenesis of IBD, and thus we believe that T cell subsets will
be ideal biomarkers in prognosis prediction for complicated CD.
Owing to the core position of Tregs in IBD,[6] we have focused
on CD8+Tregs, which are less commonly investigated than
CD4+CD25+Tregs. Our previous study showed that the balance
of circulating CD8+CD28+ andCD8+CD28–T cells, as well as the
CD8+CD28+/CD8+CD28– ratio, played a critical role in intestinal
immunity, suggesting that a high level of blood CD8+CD28+
T cells is favorable for both patients and rats with UC.[5,7]
Furthermore, we hypothesized that the CD8+CD28+/
CD8+CD28– ratio plays a significant role in prognosis; thus,
we arranged a follow-up for the patients with complicated CD at
30 weeks after diagnosis. We expected that the initial
CD8+CD28+/CD8+CD28– ratio could predict poor outcome
with high sensitivity and specificity for the complicated CD
patients. This study was conducted as follows.2. Methods
2.1. Clinical data
Our investigation was approved by the Ethics Committee of
Nanfang Hospital, Southern Medical University. The CD
patients, with clinical diagnoses according to the local endosco-
py, pathology, and pharmacy records,[8] came from the
Gastroenterology and Emergency departments of Nanfang
Hospital, SouthernMedical University, as well as the Department
of Gastroenterology, Guangdong General Hospital and Guang-
dong Academy of Medical Sciences, between October 2013 to
December 2016. CD patients with tumors, tuberculosis,
autoimmune diseases, pregnancy,[9] or poor compliance were
excluded.[10] Overall, 65 CD subjects were enrolled in this study,
ranging in age from 12 to 61 years. The study participants
included 17 complicated (the observation group) and 48 common
(the control group) CD subjects, 46 males and 19 females. There
were 8 cases who mainly suffered from penetrating (8/65,
12.31%), 12 from stricturing (12/65, 18.46%), and 6 from
perianal diseases (6/65, 9.23%); 3 from ankylosing spondylitis
(3/65, 4.62%); and 1 from uveitis (1/65, 1.54%); 7 patients
experienced at least 2 of the above-mentioned 3 complications (7/
65, 10.77%).+
2.2. Risk factor comparison
We compared the internal factors,[11] including sex, age, course
of disease, body mass index (BMI), Crohn disease activity index
(CDAI), and family history of bowel diseases, between the
complicated and control CD groups. The external factors[12]
(mainly therapeutic factors) assessed included 5-aminosalicylic
acid (5-ASA), immunosuppressants, steroids, probiotics, biolog-
ical agents (BAs), and surgery after definite diagnosis.2
2.3. Flow cytometry evaluation of CD8 T cells
CD8-FITC and CD28-PE antibodies (Santa Cruz Biotechnology,
Dallas, TX) were applied to label specific circulated T cells.[13]
Peripheral blood was drawn after definite diagnosis for CD8+ T
cell frequency testing. The antibody-labeled blood samples were
washed and fixed, and then the cells were detected by flow
cytometry (FCM) using a Beckman Coulter Epics XL flow
cytometer and System II software (Beckman Coulter, Pasadena,
CA).[5,7] FCM was also used to measure the percentages and
fluorescence intensities of the immunostained CD8+CD28+and
CD8+CD28– T cells in the sample. For each measurement, 20
104cells were counted.[6]2.4. Follow-up and prognosis prediction
A 30-week follow-up was performed and CD8+ T cells were
evaluated at the end of week 0 (before definite CD diagnosis) and
the 6th, 22nd, and 30th week after diagnosis (concomitantly with
the infliximab time points regardless of whether the CD patients
used infliximab) for all 65 CD patients. The quantities of
CD8+CD28+T cells, CD8+CD28– T cells, and the CD8+CD28+/
CD8+CD28– ratio were compared between the complicated and
control CD patients at the above-mentioned 4 time points. The
sensitivity and specificity of the initial (0 week) measurements of
the CD8+CD28+ T cells, CD8+CD28– T cells, and CD8+CD28+/
CD8+CD28– ratio in predicting the outcome were analyzed using
receiver-operating characteristic (ROC) curves. The lasting time
of remission (LTR) was calculated for the CD patients after they
were determined to be in the active stage by both clinical
manifestations and laboratory examinations. The cumulative
remission lasting rates (CRLRs) under the different risk factors
were evaluated after follow-up.2.5. Statistical analysis
Repeated measures analysis of variance was used to compare the
CD8+ T cells and their balance at different time points, and
Spearman or Pearson analyses were performed to identify the
correlations between CD8+ T cells and risk factors. ROC curves
were used to verify the predicting model for CD8+ T cells and
their balance, and the CRLRs were analyzed using the Kaplan-
Meier method. The analysis was performed using the statistical
software package SPSS 17.0, and statistical significance was
defined at P< .05.3. Results
3.1. Complicated and common CD present different risk
factors
There was no significant difference in the course of the disease,
stage, family history of bowel diseases, administration of 5-ASA,
probiotics, or BA between the complicated and control CD cases
(all P> .05). Compared with the control CD group, patients with
complicated CD were more commonly male and younger in age;
they also had lower BMIs, higher CDAIs, higher prescription
rates for immunosuppressants and steroids, and a significant
higher surgical rate (Table 1).3.2. The CD8 T cell balance is correlated with risk factors
Spearman or Pearson analysis showed that the average (from
week 0 to the 30th week) number of CD8+CD28+T cells and
+ – + + + –
Table 1
Comparison of factors between complicated and control CD (N=65 total).
Factors Classification Complicated CD (n=17) Control CD (n=48) Statistics P
Sex Male 14 (82.35%) 32 (66.67%) x2=12.138 .001
Female 3 (17.65%) 16 (33.33%)
Age, y 24.55±5.79 28.56±7.13 t=2.389 .019
BMI 15.94±2.56 18.63±2.68 t=4.107 <.0001
CDAI 454.29±39.57 217.36±90.73 t=12.488 <.0001
Course of disease, y 5.71±3.52 4.98±2.87 t=0.825 .412
Stage before definite diagnosis Remission 1 (5.88%) 7 (14.58%) Z=0.931 .439
Active 16 (94.12%) 41 (85.42%)
Family history of bowel diseases Yes 5 (29.41%) 13 (27.08%) x2=0.034 .543
No 12 (70.59%) 35 (72.92%)
5-ASA before definite diagnosis Yes 15 (88.24%) 41 (85.42%) x2=0.084 .566
No 2 (11.76%) 7 (14.58%)
Immunosuppressant before definite diagnosis Yes 16 (94.12%) 32 (66.67%) x2=4.898 .029
No 1 (5.88%) 16 (33.33%)
Steroids before definite diagnosis Yes 11 (64.71%) 44 (91.67%) Z=2.627 .015
No 6 (35.29%) 4 (8.33%)
Probiotics before definite diagnosis Yes 10 (58.82%) 26 (54.17%) x2=0.110 .483
No 7 (41.18%) 22 (45.83%)
BA use after diagnosis Yes 14 (82.35%) 35 (72.92%) Z=0.770 .528
No 3 (17.65%) 13 (27.08%)
Surgery after diagnosis Yes 8 (47.06%) 0 (0.00%) Z=5.036 <.0001
No 9 (52.94%) 48 (100.00%)
5-ASA= aminosalicylic acid, BA=biological agent, BMI=body mass index, CD=Crohn disease, CDAI=Crohn disease activity index.
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negatively correlated with CDAI, steroids, and surgery (all
P< .05). However, only the CD8+CD28+/CD8+CD28– ratio, but
not CD8+CD28+or CD8+CD28–T cells, was positively correlated
with BMI (P= .001, .324 and .363, respectively; Table 2).
3.3. The CD8+CD28+/CD8+CD28– balance is increased in
common CD but not in complicated CD
Surprisingly, the CD8+CD28+/CD8+CD28– ratio changed in
opposite directions between the complicated and control CD
patients during follow-up: the ratio apparently rose with time in
the control CD group but slightly decreased in the complicated
CD group. At all time points (weeks 0, 6, 22, and 30), the
differences in CD8+CD28+ T cells, CD8+CD28– T cells, and
CD8+CD28+/CD8+CD28– were significant between the compli-
cated and control CD groups (all P< .05, Fig. 1).
3.4. CD8+CD28+/CD8+CD28– balance can effectively
predict the poor outcome
Higher initial (before definite CD diagnosis) CD8+CD28+ T cell
levels and CD8+CD28+/CD8+CD28– ratios were found in the CDTable 2
Correlation of essential risk factors with average CD8+ T cells and t
CD8+CD28+ T cells
Factors r P
Sex 0.158 .128 0
Age 0.020 .846 0
BMI 0.103 .324 0
CDAI 0.283 .006 0
Immunosuppressant 0.162 .119 0
Steroids 0.469 .000 0
Surgery 0.260 .011 0
BMI=body mass index, CDAI=Crohn disease activity index.
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group experiencing subsequent remission (n=54, including 13 in
the complicated and 41 in the control groups) when compared to
the group subsequently experiencing active CD (n=11, including
4 in the complicated group [1 case with enterovesical fistulas] and
7 in the control group; P< .0001 and P= .001; Fig. 2A and C),
but the opposite was found for CD8+CD28– T cells (P= .045,
Fig. 2B). The LTR of the complicated group was (22.46±9.02)
weeks, which was significantly shorter than in the control group
(30.10±14.75 weeks; P= .044); LTR was correlated with
CD8+CD28+ T cells, CD8+CD28– T cells, and the CD8+
CD28+/CD8+CD28– ratio (P= .002, <.0001, and <.0001,
respectively). Statistical significance was found for the initial
CD8+CD28+ T cell and CD8+CD28– T cell levels as well as the
CD8+CD28+/CD8+CD28– ratio for predicting the subsequently
active stage in both complicated and control CD patients, with
area under ROC curve (AUC)s of 0.802, 0.338, and 0.890,
respectively (95% CIs were 0.697–0.907, 0.206–0.470, and
0.822–0.958, respectively, and P< .0001, P= .042 and P
< .0001, respectively; Table 3 and Fig. 2D). The cutoff value
showed that the best sensitivity (89.26%) and specificity
(85.32%) were found when the ratio was 1.03 (9.38%
CD8+CD28+ T cells /9.11% CD8+CD28– T cells).heir balance.
CD8+CD28– T cells CD8+CD28+/CD8+CD28–
r P r P
.008 .940 0.096 .359
.079 .447 0.026 .804
.095 .363 0.337 .001
.245 .017 0.309 .002
.146 .161 0.026 .805
.368 .000 0.470 .000
.226 .029 0.270 .009
Figure 1. The frequencies of CD8+ T cells and their balance during follow-up in complicated and control CD patients. (A, B, and C depict CD8+CD28+ T cells,
CD8+CD28– T cells, and CD8+CD28+/CD8+CD28–, respectively; a represents P< .05 when compared to week 0, whereas c represents P< .05 in complicated
compared to control CD patients.).
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outcomes
t Tests showed that CD8+CD28+ T cells and the CD8+CD28+/
CD8+CD28– ratio were significantly higher in the nonsteroid and
nonsurgery patients than in those receiving steroids or undergo-
ing surgery (all P< .05; Fig. 3A, C, D, and F), whereas the
CD8+CD28– T cell levels were significantly lower in theFigure 2. The frequencies and balance of CD8+ T cells in patients under remission
and the receiver-operating characteristic (ROC) curves evaluating the ability of CD8
CD patients (D). The diagonal line in D is the diagnostic reference line.
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nonsteroid and nonsurgery patients than in those receiving
steroids or undergoing surgery (P< .0001 and P= .031, respec-
tively; Fig. 3B and E). CRLRs were significantly higher in the
nonsteroid and nonsurgery CD subjects than in those receiving
steroids or undergoing surgery (x2=23.498 and 8.561, respec-
tively, and P< .0001 and P= .003, respectively; Fig. 4A
and B).and active Crohn disease (CD) patients before definite diagnosis (A, B, and C)
+ T cells and their balance to predict the active stage in complicated and control
Table 3
The AUCs for the ability of the initial CD8+ T cell levels and their balance to predict the subsequent active stage in CD patients.
Variables AUCs Std. error Asymptotic sig.
Asymptotic 95% confidence interval
Lower Bound Upper Bound
CD8+CD28+ T cells 0.802 0.054 <0.0001 0.697 0.907
CD8+CD28– T cells 0.338 0.067 0.042 0.206 0.470
CD8+CD28+/CD8+CD28– 0.890 0.035 <0.0001 0.822 0.958
AUCs= areas under curves, CD=Crohn disease.
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4.1. Epidemiology and risk factors of CD complications
It has been reported that the natural history of CD includes rates
of complicated disease ranging from 48% to 52% at 5 years after
diagnosis.[14] An Asian study[2] revealed that there has been a 2-
3-fold increase in IBD incidence in several countries in Asia, and
complicated and penetrating CD cases are more common in Asia
than in western countries. A Chinese study[15] also indicated that
the clinical features of IBD in China were different from those
in developed countries, regardless of age and sex distribution,
disease location and severity, or the prevalence of extraintestinal
manifestations. A total of 11 of 65 (16.92%) CD patients in our
study were younger than 18 years, and 17 of 65 (26.15%)
subjects suffered from complications, with an average disease
course of 5.3 years in our study, which was not as severe as the
CD cases in the United States.[16]
Pathologically, stricturing generates when regeneration and
repair fail to restore normal tissue architecture (as in the case of
the older female with enterovesical fistulas in Fig. 5), and
intestinal wall thickening can cause luminal narrowing.[17]
However, what clinical factors cause IBD and its complications
remain unknown.[18] To gain better understanding of the risk
factors, we classified them into 2 types: internal and external
factors. The internal factors include sex, age, age at onset, course
of disease, stage, and family history, BMI, and CDAI,[19] whereasFigure 3. CD8+ T cells in nonsteroid/nonsurgery patients (No) and patients receiv
between patients receiving steroids or not, whereas D, E, and F represent comp
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the external factors often contain therapeutic factors, such as the
administration of 5-ASA, immunosuppressants, steroids, BAs,
and surgery.[12,20] We found that no significant differences
existed in the course of disease, stage, family history of bowel
diseases, administration of 5-ASA, probiotics, and BA between
complicated and control CD, indicating that these factors could
not accelerate or retard the emergence of complications.
Conversely, we found that male sex, younger age, lower BMI,
higher CDAI, and higher rates of immunosuppressants, steroids
and surgery were the distinguishing characteristics between the 2
groups, indicating that young and thinmale CD patients are more
prone to complications, consistent with Jacobsen et al’s find-
ings.[21]
Regarding therapeutics after definite CD diagnosis, BAs are the
preferred medications if the patients have indications,[22] which is
the main reason why we chose weeks 0, 6, 22, and 30,
corresponding to the infliximab prescription schedule, as the time
points for follow-up. In our study, 49 of 65 (75.38%) subjects
received infliximab, and the remaining 16 (24.62%) subjects did
not undergo infliximab treatment because of financial difficulties.
Unfortunately, 9 of these 16 (56.25%) cases progressed to an
active stage within 30 weeks after definite diagnosis, indicating
the vital therapeutic effect of BA during a short time period,
which differed slightly from Lichtenstein et al’s report.[23] This
long-term cohort study found that the mortality was similar
between patients with infliximab treatments and those receivinging steroids or undergoing surgery (Yes). A, B, and C represent comparisons
arisons between patients undergoing surgery or not.
Figure 4. Survival plots of Crohn disease patients with or without steroid and surgery treatments. (The abscissa represents the lasting time of remission [LTR],
whereas the ordinate represents the cumulative remission lasting rates. A and B depict patients receiving steroids and surgery, respectively.) (A) The median LTR of
the nonsteroid group was 36.14 weeks, with a 95% confidence interval [CI] of 34.35–37.92, whereas the median LTR in the steroid group was 27.48 weeks, with a
95% CI of 23.01–31.95. B: The median LTR of the nonsurgery group was 35.09 weeks, with a 95% CI of 33.30–36.89, whereas the median LTR for the surgery
group was 27.90 weeks, with a 95% CI of 20.26–35.54.
Dai et al. Medicine (2017) 96:26 Medicineother treatments only, whereas an increased risk of serious
infection was observed with infliximab. Based on these data, we
think that BAs are essential for newly diagnosed CD subjects,
especially for those with complicated CD, regardless of whether
they undergo surgery.+4.2. CD8 T cells are vital in IBD follow-up
Similar to CD4+ T helper (Th) cells, CD8+ T effector (Teff) cells
are the other important T lymphocyte subset that can mount both
local and systemic immune responses in IBD pathogenesis.[24] In
mucosal immune responses, normal intestinal epithelial cells, the
unique non-dendritic cell, non-monocyte, or non-B cell special-
ized antigen presenting cells (APCs), could express major
histocompatibility complex class II molecules constitutively,Figure 5. Computed tomography (CT) and magnetic resonance imaging (MRI) sc
patient presented with abdominal pain for>10 years, with a 3-month history of clou
thickness in the far end of the ileum (arrows in A), and the nidus invaded the bladde
showed a mass convex to the enteric cavity of the ileum, with tresis and inter
anterosuperior bladder (T1-weighted, D).
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expressing some critical costimulatory molecules, such as
gp180,[25] to activate certain peripheral blood CD8+ T cells
selectively for a suppressor function.[26,27] Furthermore, Raf-
faello et al[28] have demonstrated for the first time that not only
can circulating CD8+CD28– suppressor T cells (Ts) be involved in
the differentiation of tolerogenic APCs, but they can also
suppress the TH cell response via contact mediated by APCs,
implying that CD8+CD28– suppressor T cells participate in the
maintenance of peripheral tolerance. It has been confirmed that a
lack of suppressor T cells (including CD8+CD28– T cells) induced
by intestinal epithelial cells is relevant to IBD.[29] These data agree
with Allez et al’s[30] finding that mucosal CD8+CD28– T cells can
function in anti-inflammatory roles, inhibiting the superabun-
dant immunological reaction to protect the intestinal mucosa
from pathological injuries, and CD8+CD28+ T cells cananning images of a 58-year-old female with complicated Crohn disease. This
dy urine. Enhanced CT scanning showed a nidus with wall edema and mucosal
r and shaped an eminence lesion, with a size of 3823mm (B). MRI scanning
nal fistula (T2-weighted, C), and this inflammatory mass encroached on the
+ –
+ + + –
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suppression.
Two possible mechanisms exist for how CD8+ T cells are
involved in controlling IBD. In one mechanism, after expressing
CD8a upon arrival at the intestinal epithelium, CD4+ T cells,
with double-positive expression, could upregulate the production
of interleukin (IL)-10 by suppressing TH1 on the NF-kB-GATA-
3-axis.[31] The other possible mechanism is that CD4– CD8a+b–
T cells protect against chronic intestinal inflammation in an IL-
10-dependent manner.[32] Recent studies have shown that as
subsets of CD8+ T cells, Foxp3-expressing Tregs were detected on
the lamina propria (LP) of patients with IBD at a higher level than
in healthy controls, whereas IL17-expressing TH17 cells were
higher in patients with UC than in healthy individuals. Compared
with LPMCs, both Tregs and TH17 were higher in the PBMCs of
IBD patients, indicating that the plasticity in patients with IBD is
led by distinct CD8+ T cells.[33]
It can be concluded from this literature that CD8+ T cells and
their balance are vital in IBD. However, our findings seem
to contradict the above-mentioned data. We found that the
CD8+CD28+/CD8+CD28– equilibrium changed inversely be-
tween complicated and control CD patients, particularly at the
end of the 30thweek, during follow-up: the ratio rose with time in
the control CD group but declined in the complicated CD group.
Moreover, at all of the time points (weeks 0, 6, 22, and 30), the
CD8+CD28+/CD8+CD28– ratios were significantly lower in
complicated CD patients than in control CD patients. Surpris-
ingly, it seemed that lower CD8+CD28+/CD8+CD28– ratios were
related to a worse outcome. The measurements were taken at the
end of the 6th week during follow-up, during the expectant
completion of the induced remission stage.[20,23] In the control
CD patients, the CD8+CD28+/CD8+CD28– ratios increased at
the end of the 22nd and 30th weeks, the time points belonging to
the remission stage for most patients, which was in line with
expectations. However, the ratios still decreased at these 2 time
points for the complicated CD patients, indicating a more severe
immunologic dysfunction caused by the complications.[34]
Penetrating, structuring, and anal fistula signify that more
CD8+CD28– T cells, the main force to suppress mucosal
immunity, will be consumed, and more time will thus be required
to increase the frequencies of CD8+CD28– T cells, which are
derived from CD8+CD28+ T cells.[7,35]+ + + –4.3. The CD8 CD28 /CD8 CD28 ratio can effectively
predict the active stage of CD
Funderburg et al[36] found that the plasma levels of IL-6,
interferon-a, and activated CD8+ T cells were increased in IBD
patients compared with healthy controls, drawing an association
between CD8+ T cell subsets and their cytokines. Although many
studies were conducted to find a perfect biomarker that is helpful
in the evaluation of IBD disease activity, the prognostic efficiency
is not satisfactory, and an ideal prediction model has not yet been
established.[37,38] Based on the background, we turned to an
immunological balance, the CD8+CD28+/CD8+CD28– ratio, to
validate a more powerful prediction model.
We found that a significantly lower initial CD8+CD28+/
CD8+CD28– ratio was found in the patients with subsequent
active CD than in those with subsequent remission, indicating
that CD relapse is associated with a decreased CD8+CD28+/
CD8+CD28– ratio. Because the lasting time of remission (LTR)
can directly reflect the prognosis for IBD patients,[39] and because
the patients with complicated CD had a significant shorter LTR7
than the control subjects, we therefore performed an ROC
analysis between the CD8+CD28+/CD8+CD28– ratio and the
LTR. Reassuringly, statistical significance was found for the
initial CD8+CD28+ T cell count, the CD8+CD28– T cell count,
and the CD8+CD28+/CD8+CD28– ratio for predicting the
subsequent active stage for the complicated and control CD
patients, verifying the effectiveness of this predictive model. The
greatest efficiency was found for the CD8+CD28+/CD8+CD28–
ratio, with a sizable AUC of 0.890, which was significantly larger
than CD8+CD28+ or CD8+CD28– T cells alone. More
importantly, the greatest sensitivity (89.26%) and specificity
(85.32%) were found when the ratio was 1.03, indicating the key
time when we should take action to treat CD patients, which is
novel in the prediction model field.
Regarding the underlying mechanism for the shift in CD8+ T
cells during follow-up, our contention is that there are 2 “shifts”
in vivo that are relevant to the dynamic changes in CD8+ T cells
and their balance: shifts from blood to colon as well as from
CD8+CD28+ T cells to CD8+CD28– T cells are crucial in the
development of CD.[30] In the active stage of CD, excessive
mucosal immunological reactions recruit more CD8+CD28– T
cells, playing a primary role in inhibiting intestinal inflammation
from the peripheral circulation to the bowel;[31] thus, more
circulating CD8+CD28+ T cells differentiate into CD8+CD28– T
cells to ensure a stable frequency of CD8+CD28– T cells. The
speeds of CD8+CD28+ T cell increase and CD8+CD28– T cell
decrease are not synchronous, and thus the ratiomore sensitively
reflects the state of immunity than do the two T cell populations
alone. This hypothesis supports the phenomenon of decreased
peripheral blood CD8+CD28+ T cells as well increased
CD8+CD28– T cells existing in the complicated CD patients.
Based on this analysis, we speculated that the initial
CD8+CD28+/CD8+CD28– ratio could be a sensitive biomarker
that can predict a poor outcome for the patients with
complicated CD.4.4. The CD8 CD28 /CD8 CD28 balance is correlated
with risk factors
To complete the link between immunity and clinical pheno-
types,[40] we performed correlation analysis on the CD8+CD28+/
CD8+CD28– ratio and the risk factors, and we found that this
ratio was associated with BMI, CDAI, steroids, and surgery. It is
possible that a low body weight means a poor nourishment state,
and thus weakened immunity, which contributes to higher CD
activation.[41] Because steroid use and surgery are the main
therapeutic measures and are binary variables, we subgrouped
the CD patients according to undergoing steroid/surgery status.
We were somewhat surprised that the CD8+CD28+/
CD8+CD28– ratios were significantly lower in the steroid and
surgery groups than in the nonsteroid and nonsurgery groups,
superficially indicating that steroids and surgery are the risk
factors for CD patients. Is this true? Many reports have verified
that long-term and high-dose administration of steroids can
significantly increase opportunistic infections in IBD patients;[42]
although surgery can directly remove the inflammatory foci, CD
pathogenesis, and especially the underlying immunologic
dysfunction, is not yet completely understood.[43] Thus, some
CD patients experienced recurrence after surgery, and 2 of 8
subjects in our study suffered from relapse with 30 weeks after
intestinal resection (1 subject was administered prednisone at a
dose of 50mg/day before being definitively diagnosed with CD).
These data suggest that steroids and surgery are double-edged
[6] Bisping G, Lugering N, Lutke-Brintrup S, et al. Patients with
Dai et al. Medicine (2017) 96:26 Medicineswords and that the immune state is the key factor that is closely
associated with recurrence.
Because the CRLRs can confirm comparisons of different risk
factors, we performed a Kaplan-Meier analysis and found that
CRLRs were also significantly lower in the steroid and surgery
CD group when compared to the nonsteroid and nonsurgery
group, which is also consistent with the comparison of the
CD8+CD28+/CD8+CD28– ratio, suggesting that the CD8+ T cell
balance is closely related to the outcome in CD patients. As a
consequence, the CD8+CD28+/CD8+CD28– ratio is correlated
not only with pathogenesis but also with the therapeutic
response.4.5. Conclusion and clinical significance of this study
For patients with complicated CD, depending on steroids and
surgery represents more severe disease activity and thus a
disequilibrated immunological balance; thus, treatment with
steroids or surgery should be initiated cautiously. Based on our
study, we believe that the CD8+CD28+/CD8+CD28– balance is a
novel biomarker of CD, with high sensitivity and specificity to
predict the active stage for complicated CD patients. In addition,
this ratio was also related to curative outcome. More clinically,
when the ratio is <1.03, CD patients should follow-up more
frequently so that physicians can evaluate their physical and
therapeutic state to lessen the possibility of relapse. Our study has
2 main limitations: the sample size and the length of follow-up.
Sixty-five subjects is a small number, andwe could not avoid bias;
thus, more complicated CD patients should be enrolled. A 30-
week follow-up is a relatively short time period, and some long-
term clinical manifestations cannot be observed during this
window, especially for patients who undergo BA treatments
>6 times. Moreover, how CD8+CD28+ T cells, CD8+CD28–
T cells, and the CD8+CD28+/CD8+CD28– ratio are involved in
the development of complicated CD still remains obscure and
requires further investigation.Acknowledgments
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